Pliant Therapeutics (PLRX) Competitors $1.20 +0.03 (+2.56%) Closing price 04:00 PM EasternExtended Trading$1.21 +0.01 (+0.83%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PLRX vs. AARD, OLMA, AVTE, OCGN, GLUE, AVIR, PRME, TKNO, RCKT, and LFCRShould you be buying Pliant Therapeutics stock or one of its competitors? The main competitors of Pliant Therapeutics include Aardvark Therapeutics (AARD), Olema Pharmaceuticals (OLMA), Aerovate Therapeutics (AVTE), Ocugen (OCGN), Monte Rosa Therapeutics (GLUE), Atea Pharmaceuticals (AVIR), Prime Medicine (PRME), Alpha Teknova (TKNO), Rocket Pharmaceuticals (RCKT), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. Pliant Therapeutics vs. Its Competitors Aardvark Therapeutics Olema Pharmaceuticals Aerovate Therapeutics Ocugen Monte Rosa Therapeutics Atea Pharmaceuticals Prime Medicine Alpha Teknova Rocket Pharmaceuticals Lifecore Biomedical Pliant Therapeutics (NASDAQ:PLRX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations and risk. Do insiders & institutionals believe in PLRX or AARD? 97.3% of Pliant Therapeutics shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer PLRX or AARD? Pliant Therapeutics presently has a consensus price target of $13.31, indicating a potential upside of 1,009.38%. Aardvark Therapeutics has a consensus price target of $33.00, indicating a potential upside of 144.08%. Given Pliant Therapeutics' higher possible upside, equities analysts plainly believe Pliant Therapeutics is more favorable than Aardvark Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pliant Therapeutics 0 Sell rating(s) 12 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Aardvark Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to PLRX or AARD? In the previous week, Aardvark Therapeutics had 7 more articles in the media than Pliant Therapeutics. MarketBeat recorded 8 mentions for Aardvark Therapeutics and 1 mentions for Pliant Therapeutics. Pliant Therapeutics' average media sentiment score of 0.93 beat Aardvark Therapeutics' score of 0.79 indicating that Pliant Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pliant Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aardvark Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, PLRX or AARD? Aardvark Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPliant Therapeutics$1.58M46.63-$210.30M-$3.61-0.33Aardvark TherapeuticsN/AN/A-$20.59MN/AN/A Is PLRX or AARD more profitable? Aardvark Therapeutics' return on equity of 0.00% beat Pliant Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pliant TherapeuticsN/A -67.56% -52.54% Aardvark Therapeutics N/A N/A N/A SummaryAardvark Therapeutics beats Pliant Therapeutics on 6 of the 11 factors compared between the two stocks. Get Pliant Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRX vs. The Competition Export to ExcelMetricPliant TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$71.82M$2.90B$5.49B$8.93BDividend YieldN/A2.69%5.38%4.13%P/E RatioN/A21.3126.2119.90Price / Sales46.63241.40405.84161.31Price / CashN/A41.8936.4957.06Price / Book0.247.518.055.38Net Income-$210.30M-$55.05M$3.15B$248.50M7 Day Performance-13.04%2.45%1.85%2.97%1 Month Performance-16.67%7.33%4.81%6.02%1 Year Performance-88.68%5.38%34.86%20.39% Pliant Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRXPliant Therapeutics4.244 of 5 stars$1.20+2.6%$13.31+1,009.4%-89.2%$71.82M$1.58M0.0090Gap UpAARDAardvark TherapeuticsN/A$13.33+19.8%$31.25+134.4%N/A$289.26MN/A0.0018News CoverageAnalyst ForecastAnalyst RevisionGap DownOLMAOlema Pharmaceuticals2.6734 of 5 stars$4.19+1.5%$24.50+484.7%-60.8%$286.68MN/A-2.0870News CoveragePositive NewsAVTEAerovate TherapeuticsN/A$9.89+5.1%N/A-83.2%$286.66MN/A-3.3120Gap DownHigh Trading VolumeOCGNOcugen1.3297 of 5 stars$0.98-7.4%$6.00+511.6%-43.1%$286.51M$4.52M-5.1680High Trading VolumeGLUEMonte Rosa Therapeutics1.8015 of 5 stars$4.64+0.2%$15.50+234.1%+17.0%$285.41M$75.62M58.0190Positive NewsAVIRAtea Pharmaceuticals3.1131 of 5 stars$3.32+2.2%$6.00+80.7%+6.8%$284.13MN/A-2.0170News CoveragePRMEPrime Medicine3.6756 of 5 stars$2.16+4.3%$10.08+366.8%-50.2%$283.60M$3.85M-1.05234High Trading VolumeTKNOAlpha Teknova3.0127 of 5 stars$5.28-5.0%$8.50+61.0%+307.4%$282.16M$37.74M-11.00240News CoverageRCKTRocket Pharmaceuticals4.9145 of 5 stars$2.63-2.6%$18.60+607.2%-87.5%$280.86MN/A-1.00240LFCRLifecore Biomedical1.5996 of 5 stars$7.39+6.5%$8.00+8.3%+68.6%$273.65M$128.26M-5.10690Positive News Related Companies and Tools Related Companies AARD Alternatives OLMA Alternatives AVTE Alternatives OCGN Alternatives GLUE Alternatives AVIR Alternatives PRME Alternatives TKNO Alternatives RCKT Alternatives LFCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLRX Stock Alerts